BCL2 and acute myeloid leukemia: Specifically, AML LSCs are known to preferentially rely on oxidative phosphorylation (OXPHOS) as opposed to glycolysis to maintain cellular bioenergetics, and have managed to use BCL-2-depedent mechanisms to keep the production of reactive oxygen species (ROS), byproducts of OXPHOS, at bay, which is in alignment with their slowly proliferating, quiescent properties [160,161].